BioMarin Pharmaceutical Inc. (BMRN) P/E Ratio History
UndervaluedTrading at 33.5x vs 5Y avg 157.2x · 35th percentile · Below historical baseline · Data 2008–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, BioMarin Pharmaceutical Inc. (BMRN) trades at a price-to-earnings ratio of 33.5x, with a stock price of $60.35 and trailing twelve-month earnings per share of $1.36.
The current P/E is 79% below its 5-year average of 157.2x. Over the past five years, BMRN's P/E has ranged from a low of 16.3x to a high of 966.1x, placing the current valuation at the 35th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, BMRN trades at a 44% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, BMRN commands a significant premium over the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BMRN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BMRN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BMRN P/E vs Peers
Commercial Rare Disease Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 11.4Lowest | -Best | +68% | |
| $43B | 138.0 | -Best | +207% | |
| $11B | 53.9 | -Best | +128% | |
| $7B | 11.5 | -Best | +264%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
BMRN Historical P/E Data (2008–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $56.49 | $1.39 | 40.6x | -73% |
| FY2025 Q4 | Dec 31 2025 | $59.43 | $1.80 | 33.0x | -78% |
| FY2025 Q3 | - | $54.16 | $2.66 | 20.4x | -87% |
| FY2025 Q2 | Jun 30 2025 | $54.97 | $3.37 | 16.3x | -89% |
| FY2025 Q1 | Mar 31 2025 | $70.69 | $2.69 | 26.3x | -83% |
| FY2024 Q4 | - | $65.73 | $2.20 | 29.9x | -80% |
| FY2024 Q3 | Sep 30 2024 | $70.29 | $1.67 | 42.1x | -72% |
| FY2024 Q2 | Jun 30 2024 | $82.33 | $1.33 | 61.9x | -59% |
| FY2024 Q1 | Mar 31 2024 | $87.34 | $1.07 | 81.6x | -46% |
| FY2023 Q4 | Dec 31 2023 | $96.42 | $0.87 | 110.8x | -27% |
| FY2023 Q3 | Sep 30 2023 | $88.48 | $0.76 | 116.6x | -23% |
| FY2023 Q2 | Jun 30 2023 | $86.68 | $0.51 | 169.0x | +11% |
| FY2023 Q1 | Mar 31 2023 | $97.24 | $0.37 | 260.8x | +71% |
| FY2022 Q4 | Dec 31 2022 | $103.49 | $0.73 | 141.2x | -7% |
| FY2022 Q3 | Sep 30 2022 | $84.77 | $0.41 | 204.7x | +34% |
| FY2022 Q2 | - | $82.87 | $0.25 | 331.5x | +118% |
| FY2022 Q1 | - | $77.10 | $0.17 | 453.5x | +198% |
| FY2021 Q3 | - | $77.29 | $0.08 | 966.1x | +534% |
| FY2021 Q2 | Jun 30 2021 | $83.44 | $4.29 | 19.4x | -87% |
| FY2021 Q1 | Mar 31 2021 | $75.51 | $4.06 | 18.6x | -88% |
| FY2020 Q4 | - | $87.69 | $4.41 | 19.9x | -87% |
| FY2020 Q3 | Sep 30 2020 | $76.08 | $4.37 | 17.4x | -89% |
| FY2020 Q2 | - | $123.34 | $0.66 | 186.9x | +23% |
| FY2020 Q1 | - | $84.50 | $0.61 | 138.5x | -9% |
| FY2011 Q2 | - | $27.21 | $1.48 | 18.3x | -88% |
| FY2011 Q1 | - | $25.13 | $1.53 | 16.5x | -89% |
| FY2010 Q4 | Dec 31 2010 | $26.93 | $1.58 | 17.1x | -89% |
| FY2010 Q3 | - | $22.35 | $1.73 | 12.9x | -92% |
| FY2010 Q2 | Jun 30 2010 | $18.96 | $0.11 | 171.9x | +13% |
| FY2010 Q1 | Mar 31 2010 | $23.37 | $0.13 | 187.0x | +23% |
| FY2009 Q3 | Sep 30 2009 | $18.08 | $0.19 | 95.2x | -38% |
| FY2009 Q2 | - | $15.61 | $0.14 | 111.5x | -27% |
| FY2009 Q1 | - | $12.35 | $0.17 | 72.6x | -52% |
| FY2008 Q4 | Dec 31 2008 | $17.80 | $0.32 | 55.6x | -63% |
| FY2008 Q3 | - | $26.49 | $0.10 | 278.8x | +83% |
| FY2008 Q2 | Jun 30 2008 | $28.98 | $0.03 | 940.9x | +518% |
Average P/E for displayed period: 152.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
18+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BMRN — Frequently Asked Questions
Quick answers to the most common questions about buying BMRN stock.
What is BMRN's P/E ratio?
BioMarin Pharmaceutical Inc. (BMRN) trailing twelve-month P/E ratio is 33.5x, based on TTM diluted EPS of $1.36. The 5-year average P/E is 157.2x and the historical range spans 16.3x to 966.1x.
Is BMRN stock overvalued or undervalued?
BMRN trades at 33.5x P/E, below its 5-year average of 157.2x. At the 35th percentile of its historical range (16.3x–966.1x), the stock is priced at a discount to its own history.
Is BMRN stock expensive?
No, BMRN is not expensive on a historical basis. The current P/E of 33.5x is below the 5-year average of 157.2x and sits at the 35th percentile of its valuation range.
What is BMRN's historical P/E range?
Over the past 5 years, BMRN's P/E ratio has ranged from 16.3x to 966.1x, with a median of 81.6x and an average of 157.2x. The current P/E of 33.5x places the stock at the 35th percentile of this range. Full historical data spans 2008–2026.
How does BMRN's P/E compare to the S&P 500?
BMRN trades at 33.5x P/E versus the S&P 500 median of 25.9x. The 29% premium to the market typically reflects higher expected earnings growth or quality.
How does BMRN's valuation compare to Healthcare peers?
BioMarin Pharmaceutical Inc. P/E of 33.5x compares to the Healthcare sector median of 23.4x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is BMRN's PEG ratio?
BMRN PEG ratio is N/A, based on a P/E of 33.5x and EPS growth of -18.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BMRN's earnings yield?
BMRN earnings yield is 2.98%, the inverse of its 33.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.